Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function
NCT: NCT07430332 ·
Status: NOT YET RECRUITING ·
Phase: Phase 2
· Sponsor: Children's Hospital Medical Center, Cincinnati
· Started: 2027-09-01
· Est. Completion: 2030-01-01
Official Summary
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.
Study Design
- Study Type: INTERVENTIONAL
- Allocation: RANDOMIZED
- Model: PARALLEL
- Masking: TRIPLE
- Enrollment: 15 participants
Interventions
- DRUG: Semaglutide — Study participants will be randomized to either placebo or semaglutide treatment for 12 months
- DRUG: Placebo — Randomized to either placebo or semaglutide.
Primary Outcomes
- C-peptide area under the curve (12 months)
- C-peptide area under the curve (AUC) (12 months)
Secondary Outcomes
- Stimulated incretin levels (12 months)
- Glucagon secretion (12 months)
Trial Locations
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
More Stage 1 Diabetes Mellitus, Type 1 Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.